Golden State Equity Partners Has $162,000 Stock Position in Haleon plc (NYSE:HLN)

Golden State Equity Partners lessened its holdings in shares of Haleon plc (NYSE:HLN) by 16.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 15,322 shares of the company’s stock after selling 3,097 shares during the quarter. Golden State Equity Partners’ holdings in Haleon were worth $162,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Fortitude Family Office LLC bought a new position in shares of Haleon during the 3rd quarter worth approximately $28,000. Cultivar Capital Inc. bought a new position in Haleon during the second quarter worth $40,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Haleon in the first quarter valued at $43,000. Hexagon Capital Partners LLC raised its position in shares of Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares during the period. Finally, BOKF NA lifted its stake in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after buying an additional 2,842 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on HLN shares. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. UBS Group upgraded Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. Finally, Morgan Stanley increased their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon currently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Stock Down 1.1 %

NYSE HLN opened at $9.70 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $43.89 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 2.90 and a beta of 0.26. The company has a 50 day moving average of $10.24 and a 200-day moving average of $9.24. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same period in the prior year, the firm earned $0.08 earnings per share. On average, equities research analysts expect that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.